Malaysia Pharmaceuticals and Healthcare Report Q2 2012

Business Monitor International
March 20, 2012
106 Pages - SKU: BMI3816792
Countries covered: Malaysia

BMI View: Malaysia’s longer term potential as an attractive pharmaceutical market will remain shaped by theprevailing economic conditions and the export situation, which are crucial for the country’s overall economicdevelopment and thus also the availability of individual funding for medicines, given the high out-of-pocketcontribution to healthcare. Nevertheless, volume demand will continue to grow on the back of demographic andepidemiological changes, supported by the expansion of modernisation of healthcare provision in both public andprivate sectors.

Headline Expenditure Projections

.. Pharmaceuticals: MYR4.92bn (US$1.61bn) in 2011 to MYR5.23bn (US$1.64bn) in 2012; +5.9% in localcurrency and +2.1% in US dollars. Forecast down slightly from Q212 due to macroeconomic factors.

.. Healthcare: MYR38.93bn (US$12.73bn) in 2011 to MYR41.32bn (US$13.01bn) in 2012; +6.1% in localcurrency and +2.3% in US dollars. Forecast down slightly from Q212 due to macroeconomic factors.

.. Medical devices: MYR3.82bn (US$1.25bn) in 2011 to MYR4.00bn (US$1.26bn) in 2012; +4.9% in localcurrency and +1.1% in US dollars. Forecast broadly unchanged from Q212.

Business Environment Rating: In our latest proprietary Pharmaceutical Risk/Reward Rating (RRR) matrix for AsiaPacific, Malaysia ranks in an unchanged position 8 out of the 18 countries surveyed regionally. The country’srewards are considered modest at best, given the low per capita spending on pharmaceuticals, but its matrix positioncontinues to be supported by the strong risk scores.

Key Trends & Developments

.. In January 2012, Malaysian Minister of Health Liow Tiong Lai stated that a dengue fever vaccine will beavailable in the country by 2014 or 2015. The health ministry is set to enter the third phase of clinical trialson a vaccine by the end of 2012. Liow said the ministry achieved success during the second phase of trials,which involved monitoring about 2,000 people from Penang and Putrajaya. The ministry and Frenchdrugmaker Sanofi have been developing the vaccine to treat dengue.

BMI Economic View: Despite a better-than-expected real GDP growth reading of 5.2% year-on-year (y-o-y) inQ411, we are happy to maintain our below consensus view on the Malaysian economy in 2012. Our core view thatcooling global demand will continue to drag on production of cyclical goods – including industrial metals andelectrical and electronic components – means that we expect manufacturing sector growth to remain weak goingforward. Accordingly, we expect Malaysia's real GDP growth to come in at a subdued 3.3% in 2012, compared toconsensus forecast of 4.2%.

BMI Political View: The opposition Democratic Action Party (DAP) has proposed new measures aimed ataddressing corruption. Some of the key measures include a ban on political parties' involvement in businesses and theadoption of an open tender system for government contracts. DAP Secretary General Lim Guan Eng said thateconomic losses due to corruption are close to estimates published by Washington-based financial watchdog GlobalFinancial Integrity (GFI) at MYR1.1bn (US$0.3bn) annually. We believe that the move will put further pressure onthe ruling Barisan Nasional to speed up efforts to tackle corruption.



More Manufacturing, Packaging & Detailing reports by Business Monitor International

Pharmaceuticals and Healthcare Report Q3 2014 - Spain by Business Monitor International
Spain Pharmaceuticals and Healthcare Report Q3 2014BMI View: The weakened Spanish economy and the government's ongoing multi-faceted strategy to containexpenditure on prescription medicines by targeting ...
Pharmaceuticals and Healthcare Report Q3 2014 - Slovakia by Business Monitor International
Slovakia Pharmaceuticals and Healthcare Report Q3 2014BMI View: The Slovakian government is planning to allocate EUR278mn (USD386.7mn) in EU funding todevelop healthcare and medical infrastructure ...
Pharmaceuticals and Healthcare Report Q3 2014 - Serbia by Business Monitor International
Serbia Pharmaceuticals and Healthcare Report Q3 2014The new Serbian government is actively trying to stabilise the country's fiscal position through cuttingspending, encouraging outside investment and ...
Pharmaceuticals and Healthcare Report Q3 2014 - Moldova by Business Monitor International
Moldova Pharmaceuticals and Healthcare Report Q3 2014BMI View: BMI has upgraded its forecast for Moldova's pharmaceutical and healthcare market for 2014due to improved economic conditions. ...
See all reports like this >>

More Malaysia Manufacturing, Packaging & Detailing reports

Malaysia Pharmaceuticals and Healthcare Report Q2 2014 by Business Monitor International
Malaysia Pharmaceuticals and Healthcare Report Q2 2014BMI View: Malaysia's pharmaceutical and healthcare markets continue to show strong growth, and thegovernment's 2014 budget allocation for the ...
Malaysia Healthcare Industry 1H13 by Emerging Markets Direct Reports
Malaysia: Healthcare covers the country's healthcare industry overview in terms of healthcare services, health human resources, healthcare expenditure and private market size. It also covers ...
Malaysia Pharmaceuticals and Healthcare Report Q1 2013 by Business Monitor International
BMI View: Malaysia's healthcare sector is showing strong signs of growth, with increased internal andinvestment in pharmaceutical manufacturing facilities in a move to boost exports. ...
Malaysia Pharmaceuticals and Healthcare Report Q4 2012 by Business Monitor International
BMI View: Malaysia may have one of the region’s lowest per capita spend in terms of healthcare as apercentage of GDP – 4.3% in 2011 ...
See all reports like this >>

More Malaysia reports

D&B Country RiskLine Report: Malaysia by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
PCs – Malaysia – a snapshot (2010) by Mintel - Snapshots
PCs in Malaysia by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. This market covers desktop ...
See all reports like this >>

 

SELECT A LICENSE

    Report with 3 quarterly updates  USD 1,175  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!